Datasheet is currently unavailable. Try again or CONTACT US
Swine H1N1 Hemagglutinin Antibody
Rabbit Polyclonal
600-401-EX4
100 µg
Liquid (sterile filtered)
ELISA
Virus
Rabbit
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-Swine H1N1 Hemagglutinin (RABBIT) Antibody - 600-401-EX4
Swine H1N1 Hemagglutinin Antibody
Rabbit
Polyclonal
IgG
Target Details
HA - View All HA Products
Virus
Conjugated Peptide
Anti-Hemagglutinin antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide from the novel swine influenza Hemagglutinin protein.<br><br>The peptide sequence is unique from the peptide sequence for product 5237 and 5233.<br><br>This antibody is a cognate pair with product number 5239.
Anti-Swine H1N1 Hemagglutinin Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. This antibody is specific for the novel swine influenza Hemagglutinin and will not recognize the corresponding Hemagglutinin sequence from the seasonal H1N1 influenza (A/Brisbane/59/2007 (H1N1)). Will not cross-react with peptide corresponding to the seasonal H1N1 Hemagglutinin.
A8UDQ2 - UniProtKB
Application Details
ELISA
Anti-Swine H1N1 Hemagglutinin Antibody has been tested for use in ELISA. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 63 kDa in Western Blots of specific cell lysates and tissues.
Formulation
1 mg/mL by UV absorbance at 280 nm
0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
0.02% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
